Showing results (91-100 of 98) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Leukemia|August 2, 2017
Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trialH Goldschmidt, H M Lokhorst, E K Mai, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.Future Oncology (London, England)|March 26, 2021
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myelomaRoman Hájek, Jiří Minařík, Jan Straub, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Genomic Classification and Individualized Prognosis in Multiple MyelomaFrancesco Maura, Arjun Raj Rajanna, Bachisio Ziccheddu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2026
Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 TrialJia Xiang Jin, Varun R Ginde, Stefanie Huhn, et al.Blood Cancer Journal|March 26, 2026
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myelomaShaji Kumar, Sundar Jagannath, Katja C Weisel, et al.The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.Pageof 10